Cigna Implements 340B Program Workaround as Walgreens Invests in Pharmacy Automation

In March 2026, several developments in the pharmaceutical and healthcare sectors have drawn attention. Key updates include Cigna’s strategic move to integrate vertically within the 340B program, Merck’s decision to lower drug prices while Medicaid and 340B programs face increased costs, Walgreens’ investment in pharmacy automation technology, and an analysis of how rebates on highly rebated drugs impact patients financially. Additionally, a photo from the Drug Channels Leadership Forum was shared as part of this month’s roundup.

Cigna has implemented a workaround within the 340B program that aligns with its vertical integration strategy. This approach aims to optimize operations within the complex framework of drug pricing and distribution. Meanwhile, Merck announced price reductions for certain medications under ARPA (American Rescue Plan Act), but these changes reportedly result in higher payments from Medicaid and entities participating in the 340B program. Walgreens is making significant investments in automation technology for its pharmacies, signaling a shift toward modernizing operations to improve efficiency. Another report highlights how health plans benefit financially from highly rebated drugs while patients often bear higher out-of-pocket costs due to rebate structures. Lastly, attendees of the Drug Channels Leadership Forum were treated to a group photo showcasing industry leaders gathered at the event.

These developments underscore ongoing shifts across various aspects of healthcare delivery and pharmaceutical management as organizations adapt to regulatory changes, technological advancements, and evolving market dynamics.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: March 31, 2026

Author

GOAI